A brief overview of the key points discussed during a company’s quarterly earnings call, including financial performance, guidance, and management’s commentary on future outlook.
S2Medical Earnings
Estimates
Actual
Y-on-Y Change
Revenue
EPS
Transcripts
Events
About S2Medical AB (publ)
S
S
S2Medical AB (publ)
S2M
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. It offers Epiprotect 2117, a synthetic allograft/xenograft substitute; Epiprotect Ulcer, a wound dressing consisting of a thin film of biosynthetic cellulose polymer intended to be used as a protective barrier for superficial wounds and deep wounds that have breached the dermis, as well as used as a temporary coverage for deep extensive wounds before transplantation or other surgical intervention. The company also provides washable, durable, waterproof, and self-adhesive bandages under the INSTABIND brand name, as well as NO SMELL, a perfume-free odour remover; BIOPAD, an ivory-white soft sponge; and INSTAQRETT, a sterile mechanical debridement tool for, among other things, multi-resistant Staphylococci. In addition, it offers IvaQ, CE-marked negative pressure wound therapy; Instagraft, designed to make advanced skin transplantation; ADMERCIN, next-generation antimicrobial peptide technology; Symbiovance, peptide-based functional skincare; Eyracure, a patented light-activated peptide technology that repairs damaged hair at the molecular level; and Eiratex, advanced biosynthetic polymer for next-generation wound healing applications. Further, the company operates the wound healing center under the S2Clinic name. The company was incorporated in 2013 and is headquartered in Linköping, Sweden.
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. It offers Epiprotect 2117, a synthetic allograft/xenograft substitute; Epiprotect Ulcer, a wound dressing consisting of a thin film of biosynthetic cellulo...
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. It offers Epiprotect 2117, a synthetic allograft/xenograft substitute; Epiprotect Ulcer, a wound dressing consisting of a thin film of biosynthetic cellulose polymer intended to be used as a protective barrier for superficial wounds and deep wounds that have breached the dermis, as well as used as a temporary coverage for deep extensive wounds before transplantation or other surgical intervention. The company also provides washable, durable, waterproof, and self-adhesive bandages under the INSTABIND brand name, as well as NO SMELL, a perfume-free odour remover; BIOPAD, an ivory-white soft sponge; and INSTAQRETT, a sterile mechanical debridement tool for, among other things, multi-resistant Staphylococci. In addition, it offers IvaQ, CE-marked negative pressure wound therapy; Instagraft, designed to make advanced skin transplantation; ADMERCIN, next-generation antimicrobial peptide technology; Symbiovance, peptide-based functional skincare; Eyracure, a patented light-activated peptide technology that repairs damaged hair at the molecular level; and Eiratex, advanced biosynthetic polymer for next-generation wound healing applications. Further, the company operates the wound healing center under the S2Clinic name. The company was incorporated in 2013 and is headquartered in Linköping, Sweden.
Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach. Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
